https://www.nasdaq.com/press-release/agios-to-present-at-40th-annual-j.p.-morgan-healthcare-conference-on-wednesday
https://www.nasdaq.com/press-release/agios-presents-mitapivat-long-term-extension-data-demonstrating-durability-of
https://www.nasdaq.com/press-release/agios-presents-mitapivat-data-highlighting-long-term-safety-profile-and-durable
https://www.nasdaq.com/press-release/agios-announces-data-from-investigator-led-studies-of-mitapivat-in-adults-with-sickle
https://www.nasdaq.com/press-release/agios-appoints-richa-poddar-as-chief-commercial-officer-2021-11-15
https://www.nasdaq.com/press-release/agios-to-present-broad-set-of-clinical-and-translational-data-in-chronic-hemolytic
https://www.nasdaq.com/press-release/centogene-expands-partnership-with-agios-to-generate-novel-insights-into-rare-blood
https://www.nasdaq.com/press-release/agios-reports-business-highlights-and-third-quarter-2021-financial-results-2021-11-03
https://www.nasdaq.com/press-release/agios-to-webcast-conference-call-of-third-quarter-2021-financial-results-on-nov.-3
https://www.nasdaq.com/press-release/agios-to-present-at-september-investor-conferences-2021-08-30
https://www.nasdaq.com/press-release/agios-announces-fda-acceptance-and-priority-review-of-new-drug-application-for
https://www.nasdaq.com/press-release/agios-reports-business-highlights-and-second-quarter-2021-financial-results-2021-07
https://www.nasdaq.com/press-release/agios-to-webcast-conference-call-of-second-quarter-2021-financial-results-on-july-29
https://www.nasdaq.com/press-release/agios-submits-marketing-authorisation-application-to-european-medicines-agency-for
https://www.nasdaq.com/press-release/agios-launches-myagiosr-patient-support-services-for-pyruvate-kinase-deficiency-2021
https://www.nasdaq.com/press-release/agios-submits-new-drug-application-to-fda-for-mitapivat-for-treatment-of-adults-with
https://www.nasdaq.com/press-release/agios-presents-positive-results-from-phase-2-study-of-mitapivat-in-non-transfusion
https://www.nasdaq.com/press-release/agios-announces-updated-data-from-activate-and-activate-t-phase-3-studies-of
https://www.nasdaq.com/press-release/agios-to-present-updated-data-from-clinical-trials-of-mitapivat-in-pyruvate-kinase
https://www.nasdaq.com/press-release/agios-reports-business-highlights-and-first-quarter-2021-financial-results-2021-04-29
https://www.nasdaq.com/press-release/agios-to-webcast-conference-call-of-first-quarter-2021-financial-results-on-april-29
https://www.nasdaq.com/press-release/agios-announces-closing-of-oncology-business-sale-to-servier-2021-04-01
https://www.nasdaq.com/press-release/agios-shareholders-approve-sale-of-oncology-business-to-servier-2021-03-25
https://www.nasdaq.com/press-release/agios-sponsors-program-promoting-health-literacy-for-patients-with-sickle-cell
https://www.nasdaq.com/press-release/agios-submits-supplemental-new-drug-application-to-fda-for-tibsovor-ivosidenib
https://www.nasdaq.com/press-release/agios-recognizes-14th-annual-rare-disease-day-and-raises-awareness-of-unmet-needs-in
https://www.nasdaq.com/press-release/agios-reports-fourth-quarter-and-full-year-2020-financial-results-2021-02-25
https://www.nasdaq.com/press-release/agios-to-present-at-march-investor-conferences-2021-02-23
https://www.nasdaq.com/press-release/agios-to-webcast-conference-call-of-fourth-quarter-and-year-end-2020-financial
https://www.nasdaq.com/press-release/agios-announces-phase-3-activate-t-trial-of-mitapivat-achieved-primary-endpoint-in
https://www.nasdaq.com/press-release/agios-presents-final-data-from-phase-3-claridhy-study-of-tibsovor-ivosidenib-tablets
https://www.nasdaq.com/press-release/agios-highlights-2021-milestones-to-accelerate-and-expand-its-genetically-defined
https://www.nasdaq.com/press-release/agios-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-on-monday
https://www.nasdaq.com/press-release/agios-to-focus-on-developing-and-commercializing-innovative-treatments-for
https://www.nasdaq.com/press-release/agios-announces-updated-data-from-phase-1-study-of-mitapivat-first-in-class-pkr
https://www.nasdaq.com/press-release/agios-announces-the-phase-3-activate-trial-of-mitapivat-achieved-its-primary-endpoint
https://www.nasdaq.com/press-release/agios-launches-anemia-id-a-no-cost-genetic-testing-program-for-hereditary-anemias
https://www.nasdaq.com/press-release/agios-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference-on
https://www.nasdaq.com/press-release/agios-announces-fda-orphan-drug-designation-granted-to-mitapivat-for-treatment-of-0
https://www.nasdaq.com/press-release/agios-reports-business-highlights-and-third-quarter-2020-financial-results-2020-11-05
https://www.nasdaq.com/press-release/agios-to-present-broad-set-of-clinical-and-translational-data-for-oncology-and-rare-0
https://www.nasdaq.com/press-release/agios-to-host-a-webinar-on-its-pyruvate-kinase-r-pkr-activation-clinical-programs-and
https://www.nasdaq.com/press-release/agios-to-webcast-conference-call-of-third-quarter-2020-financial-results-on-november
https://www.nasdaq.com/press-release/agios-announces-withdrawal-of-european-marketing-authorization-application-for
https://www.nasdaq.com/press-release/agios-announces-final-overall-survival-data-from-phase-3-claridhy-study-of-tibsovor
https://www.nasdaq.com/press-release/agios-appoints-jonathan-biller-as-chief-financial-officer-head-of-legal-and-corporate
https://www.nasdaq.com/press-release/agios-to-present-at-the-citi-15th-annual-biopharma-virtual-conference-on-wednesday
https://www.nasdaq.com/press-release/agios-to-present-at-the-virtual-canaccord-40th-annual-growth-conference-on-thursday
https://www.nasdaq.com/press-release/agios-reports-business-highlights-and-second-quarter-2020-financial-results-2020-07
https://www.nasdaq.com/press-release/agios-to-webcast-conference-call-of-second-quarter-2020-financial-results-on-july-30
https://www.nasdaq.com/press-release/agios-to-present-at-the-bmo-2020-prescriptions-for-success-healthcare-virtual
https://www.nasdaq.com/press-release/agios-and-royalty-pharma-announce-%24255-million-purchase-agreement-for-idhifar-royalty
https://www.nasdaq.com/press-release/agios-first-in-class-pkr-activator-mitapivat-demonstrates-sustained-hemoglobin
https://www.nasdaq.com/press-release/agios-announces-clinical-proof-of-concept-has-been-established-in-phase-1-study-of
https://www.nasdaq.com/press-release/agios-announces-fda-orphan-drug-designation-granted-to-mitapivat-for-treatment-of
https://www.nasdaq.com/press-release/agios-presents-updated-data-from-the-phase-1-dose-escalation-study-of-vorasidenib-in
https://www.nasdaq.com/press-release/agios-announces-publication-of-tibsovor-phase-3-data-in-the-lancet-oncology
https://www.nasdaq.com/press-release/agios-to-present-updated-clinical-proof-of-concept-data-from-the-phase-2-study-of
https://www.nasdaq.com/press-release/agios-to-present-updated-data-from-the-phase-1-study-of-vorasidenib-in-non-enhancing
https://www.nasdaq.com/press-release/agios-to-present-at-the-rbc-capital-markets-global-healthcare-virtual-conference-on
https://www.nasdaq.com/press-release/agios-reports-first-quarter-2020-financial-results-and-provides-update-on-business
https://www.nasdaq.com/press-release/agios-to-webcast-conference-call-of-first-quarter-2020-financial-results-on-april-30
https://www.nasdaq.com/press-release/agios-receives-positive-opinion-on-orphan-drug-designation-from-the-european
https://www.nasdaq.com/press-release/agios-provides-update-on-2016-collaboration-agreement-with-celgene-a-wholly-owned
https://www.nasdaq.com/press-release/agios-announces-fda-clearance-of-investigational-new-drug-application-for-ag-946-a
https://www.nasdaq.com/press-release/agios-to-present-at-the-cowen-40th-annual-healthcare-conference-on-tuesday-march-3
https://www.nasdaq.com/press-release/agios-reports-fourth-quarter-and-full-year-2019-financial-results-2020-02-13
https://www.nasdaq.com/press-release/agios-to-present-at-the-leerink-9th-annual-global-healthcare-conference-on-tuesday
https://www.nasdaq.com/press-release/agios-to-webcast-conference-call-of-fourth-quarter-and-full-year-2019-financial
https://www.nasdaq.com/press-release/agios-announces-agios-2025-strategic-vision-and-highlights-2020-milestones-2020-01-12
https://www.nasdaq.com/press-release/agios-to-present-at-the-38th-annual-j.p.-morgan-healthcare-conference-on-monday
https://www.nasdaq.com/press-release/agios-receives-fda-breakthrough-therapy-designation-for-tibsovor-ivosidenib-for-the
https://www.nasdaq.com/press-release/agios-presents-updated-data-for-mitapivat-from-extension-phase-of-the-drive-pk-study
https://www.nasdaq.com/press-release/agios-presents-translational-data-to-further-characterize-the-role-of-tibsovor
https://www.nasdaq.com/press-release/agios-establishes-proof-of-concept-for-mitapivat-in-non-transfusion-dependent
https://www.nasdaq.com/press-release/agios-appoints-bruce-car-ph.d.-as-chief-scientific-officer-2019-12-02
https://www.nasdaq.com/press-release/agios-appoints-jonathan-biller-as-chief-legal-officer-2019-11-25
https://www.nasdaq.com/press-release/agios-presents-new-pharmacodynamic-and-response-data-from-both-cohorts-of-the
https://www.nasdaq.com/press-release/agios-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase
https://www.nasdaq.com/press-release/agios-announces-pricing-of-%24256-million-public-offering-of-common-stock-2019-11-07
https://www.nasdaq.com/press-release/agios-announces-proposed-offering-of-common-stock-2019-11-06
https://www.nasdaq.com/press-release/agios-to-present-broad-set-of-clinical-and-translational-data-for-oncology-and-rare
https://www.nasdaq.com/press-release/agios-reports-business-highlights-and-third-quarter-2019-financial-results-2019-10-31
https://www.nasdaq.com/press-release/agios-presents-data-from-single-agent-dose-escalation-arm-of-phase-1-study-of-ag-270
https://www.nasdaq.com/press-release/agios-to-webcast-conference-call-of-third-quarter-2019-financial-results-on-october
https://www.nasdaq.com/press-release/agios-to-present-data-from-ag-270-phase-1-dose-escalation-study-in-patients-with-mtap
https://www.nasdaq.com/press-release/data-from-agios-phase-3-claridhy-trial-of-tibsovor-demonstrates-significant
https://www.nasdaq.com/press-release/agios-to-present-data-from-the-phase-3-claridhy-study-of-tibsovor-in-previously
